#adalimumab indication

[drpedi07]

Adalimumab Drug

Medical information for Adalimumab on Pediatric Oncall including Indication, Dosing, Adverse Effect, Hepatic Dose.

[roshankumar7904800]

Tumor Necrosis Factor Inhibitor Drugs Market

Tumor Necrosis Factor Inhibitor Drug Market Size, Share, Trends: AbbVie Inc. Leads

Increasing Adoption of Biosimilars Driving Market Growth

Market Overview:

The Tumor Necrosis Factor (TNF) Inhibitor Drug Market is expected to develop at a CAGR of 4.5% between 2024 and 2031. The market value is predicted to rise from XX USD in 2024 to YY USD in 2031. North America currently dominates the market, owing to its high frequency of autoimmune illnesses and modern healthcare infrastructure. Key metrics include increased R&D activity, increased biologics adoption, and increased awareness of autoimmune illnesses. The market is steadily expanding due to the rising prevalence of inflammatory illnesses such as rheumatoid arthritis and psoriasis. Technological developments in drug delivery technologies as well as the introduction of biosimilars are helping to drive market growth. However, the high cost of TNF inhibitor medications and severe side effects may limit growth to some extent.

DOWNLOAD FREE SAMPLE

Market Trends:

The TNF inhibitor medicines industry is seeing a considerable shift towards the use of biosimilars. As the patents on original biologics expire, pharmaceutical companies are creating biosimilar TNF inhibitors. These biosimilars deliver equivalent efficacy at a cheaper cost, appealing to both healthcare professionals and patients. The introduction of biosimilars is increasing access to TNF inhibitor medicines, especially in emerging economies where cost has been a significant barrier. This trend is altering the competitive landscape and propelling overall market expansion by expanding patient access and treatment alternatives.

Market Segmentation:

Adalimumab, sold under a variety of brand names, has retained its position as the leading TNF inhibitor medicine in terms of market share and income. Its success is due to its wide variety of approved indications, which include rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. The drug's efficacy, paired with its easy subcutaneous administration, has made it a popular choice among both healthcare practitioners and patients. Recent clinical trials have broadened adalimumab's possible usage. Phase III research published in the New England Journal of Medicine found it effective in treating moderate to severe hidradenitis suppurativa, a chronic inflammatory skin condition. This new indication has created new market potential for Adalimumab.

Market Key Players:

The TNF inhibitor drug market is highly competitive, with major players focusing on innovation and strategic collaborations. Key companies such as AbbVie Inc., Johnson & Johnson, Amgen Inc., Pfizer Inc., Novartis AG, UCB S.A., Bristol-Myers Squibb Company, Merck & Co., Inc., Biogen Inc., and Samsung Bioepis Co., Ltd. dominate the market.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[heathcareforallworld]

Ocular Inflammation Therapeutics Market Growth and Trends: Forecast to 2032

The Ocular Inflammation Therapeutics Market is expected to witness significant growth over the forecast period leading to 2032. Ocular inflammation refers to swelling, redness, and discomfort caused by various conditions affecting the eye, such as uveitis, keratitis, conjunctivitis, and scleritis. These conditions can arise from infections, autoimmune disorders, or trauma, potentially leading to vision loss if not treated promptly. The increasing prevalence of eye-related disorders, advancements in treatment options, and the growing elderly population are key factors propelling the market's expansion.

Ocular Inflammation Therapeutics Market Size was estimated at 14.16 (USD Billion) in 2023. The Ocular Inflammation Therapeutics Market Industry is expected to grow from 14.89(USD Billion) in 2024 to 22.2 (USD Billion) by 2032. The Ocular Inflammation Therapeutics Market CAGR (growth rate) is expected to be around 5.12% during the forecast period (2025 - 2032).

Market Growth Drivers

Rising Prevalence of Ocular Inflammatory Conditions The increasing incidence of eye diseases, particularly among the aging population, is a major factor driving the demand for ocular inflammation therapeutics. Conditions such as uveitis, which affects the uveal tract of the eye, are increasingly diagnosed globally. According to the American Academy of Ophthalmology, uveitis is responsible for 10% to 15% of cases of total blindness in the U.S. alone. Other conditions such as scleritis and keratitis are also contributing to the rising demand for effective treatments.

Increasing Awareness and Early Diagnosis Awareness campaigns promoting eye health and early diagnosis of ocular inflammatory diseases are contributing to market growth. With advancements in diagnostic technologies, such as Optical Coherence Tomography (OCT) and fundus imaging, clinicians are better equipped to identify inflammation in its early stages. This leads to more prompt and effective treatment, enhancing patient outcomes and driving the demand for therapeutic solutions.

Advancements in Therapeutics and Drug Development Innovations in the field of ocular drug delivery and therapy are helping boost the market. The development of biologics, immunosuppressants, and corticosteroid formulations has transformed the treatment landscape for ocular inflammation. For example, corticosteroid implants and injectable therapies offer sustained drug release, providing long-term relief from chronic conditions like uveitis. Additionally, novel biologic therapies are emerging as targeted treatments that offer fewer side effects compared to traditional options, thus increasing adoption.

Market Segmentation

The Ocular Inflammation Therapeutics Market can be segmented based on drug class, indication, distribution channel, and geography.

By Drug Class: The market is segmented into corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, and biologics. Corticosteroids currently hold the largest share due to their widespread use in treating inflammation, although biologics are expected to see the highest growth owing to their targeted action and fewer side effects.

By Indication: Key conditions treated include uveitis, keratitis, conjunctivitis, and scleritis. Uveitis accounts for a significant portion of the market due to its frequency and potential severity.

By Distribution Channel: The primary distribution channels are hospital pharmacies, retail pharmacies, and online pharmacies. With the increasing prevalence of e-commerce and telemedicine, online pharmacies are expected to witness notable growth over the forecast period.

Key Market Trends

Biologics Gaining Traction Biologic therapies are gaining ground in the ocular inflammation therapeutics market due to their precision in targeting specific pathways involved in the inflammatory response. Biologics like adalimumab have shown significant efficacy in treating severe uveitis, reducing the need for long-term corticosteroid use and minimizing associated side effects. As more biologic treatments receive regulatory approvals, their use is expected to expand, fueling market growth.

Rising Focus on Sustained Drug Delivery The development of sustained drug delivery systems for ocular therapeutics is a growing trend. Implants and injectables that deliver medications over an extended period are becoming more popular, especially for chronic conditions like posterior uveitis. These systems improve patient compliance, reduce the frequency of dosing, and provide more consistent therapeutic outcomes.

Increasing Use of Immunosuppressants Immunosuppressants, traditionally used in organ transplantation, are now being repurposed for treating ocular inflammatory conditions, particularly in patients unresponsive to corticosteroids. Drugs like cyclosporine and tacrolimus are gaining traction as they offer long-term control of inflammation without the side effects of prolonged steroid use.

Regional Analysis

North America holds the largest share of the ocular inflammation therapeutics market due to its advanced healthcare infrastructure, high prevalence of eye diseases, and growing geriatric population. The U.S. remains a major contributor to market growth, with high healthcare spending and an increasing number of clinical trials focused on novel therapies for ocular inflammation.

Europe follows closely, with countries like Germany, France, and the U.K. leading the way in adopting advanced ocular treatments. Awareness campaigns and government initiatives aimed at preventing vision impairment are driving market demand in this region.

Asia-Pacific is expected to witness the fastest growth during the forecast period, driven by improving healthcare infrastructure, increasing access to treatment, and a large, aging population. The rising incidence of diabetes, a key risk factor for ocular inflammation, further propels the demand for therapeutics in countries like India and China.

Competitive Landscape

Key players in the AbbVie ,Novartis ,Pfizer ,Roche ,Allergan ,Regeneron ,Alcon ,Takeda ,Iluvien ,Bausch & Lomb ,Biogen ,Santen ,Bayer ,Merck & Co ,Johnson & Johnson. These companies are focusing on product development, strategic collaborations, and mergers and acquisitions to strengthen their market presence. Ongoing research into new drug formulations, biologics, and drug delivery systems is expected to create new growth opportunities in the coming years.

Conclusion

The Ocular Inflammation Therapeutics Market is poised for substantial growth through 2032, driven by increasing awareness of eye health, advancements in drug development, and the rising prevalence of ocular inflammatory conditions. Innovations in biologics, sustained drug delivery systems, and early diagnosis technologies will continue to shape the market. As the demand for effective therapies grows, especially in emerging markets, key players in the industry are well-positioned to capitalize on these opportunities, driving future expansion.

[mediwinpharma]

Top Demand Drug companies in India in the Last Decade

Over the past decade, the demand for drug companies in India has significantly increased, reflecting the country's evolving healthcare industry. In fact, a report by Statista indicates that the Indian healthcare and pharmaceuticals sector is anticipated to experience an extraordinary growth rate of 754% between 2017 and 2060.

As India emerges as a major player in the pharmaceutical industry, it is critical to understand the demand for various drugs in the country. It provides valuable insights into the health concerns of the people, the shifting demographics, and the evolving medical requirements.

So, read the article below to gain in-depth knowledge about high-demand drugs in India and the factors influencing this demand. This knowledge can help drug companies to focus their R&D and production to cater to the specific needs of the Indian market.

Top 8 Demand Drugs in India

Some of the best drugs in India and their uses are given below:

1. Humira

Humira (adalimumab) is a widely used biological medication known for its effectiveness in treating various conditions. It functions as a tumor necrosis blocker, which helps suppress the immune system by blocking the activity of factor-α (TNF). TNF is a protein associated with inflammation and autoimmune diseases.

Uses

Treats rheumatoid arthritis in adults.

Indicated for adults with hidradenitis suppurativa (HS).

Tackles chronic plaque psoriasis.

Treats non-infectious intermediate, posterior, and panuveitis.

Approved for adult patients with active ulcerative colitis.

Used to reduce signs and symptoms of active ankylosing spondylitis.

2. Keytruda

Keytruda is a cancer medication that contains the active substance pembrolizumab. It belongs to a class of drugs known as immune checkpoint inhibitors. Keytruda blocks a protein called PD-1 in immune cells. This allows the immune system to recognize and attack cancer cells.

Uses

Treats advanced or metastatic melanoma.

Treats advanced NSCLC.

Treats children with classical Hodgkin lymphoma.

Treats advanced renal cell carcinoma.

Used in combination with chemotherapy or other cancer medicines to treat oesophageal cancer.

Prevents blood clots in cases like broken bones, immobility, surgeries, etc.

3. Eliquis

Eliquis is a prescription medication that belongs to the class of drugs known as anticoagulants or blood thinners. It is considered an anticoagulant because apixaban is its active ingredient. Eliquis is FDA-approved for treating and preventing dangerous blood clots that can block blood vessels in the body.

Uses

Treats deep vein thrombosis (DVT).

Prevents stroke.

Treats pulmonary embolism (PE).

Reduces the risk of systemic embolism.

Avoids thromboembolic events in individuals with chronic kidney disease.

Used as an anticoagulant therapy during cardiac catheterization procedures

4. Revlimid

Revlimid is a medication that contains the drug lenalidomide. It is a thalidomide analog, an immunomodulatory drug (IMiD) with various putative molecular targets and biological effects. Revlimid is primarily used to treat multiple types of cancers affecting blood cells.

Uses

Used in combination with dexamethasone for the treatment of multiple myeloma.

Used as maintenance therapy after an autologous hematopoietic stem cell transplant (auto-HSCT).

Treats lymphoplasmacytic lymphoma.

Used off-label for the treatment of systemic light-chain amyloidosis.

Tackles myelodysplastic syndromes.

Used in combination with rituximab to treat follicular and marginal zone lymphoma.

5. Imbruvica

Imbruvica is a medication available in tablet and capsule forms that are taken orally once a day. Its active ingredient is ibrutinib. Ibrutinib works by inhibiting specific proteins in cancer cells, slowing their growth, and preventing the spread of cancer.

Uses

Treats mantel cell lymphoma (MCL).

Treats chronic lymphocytic leukemia (CLL).

Tackles small lymphocytic lymphoma (SLL).

Treats waldenström's macroglobulinemia (WM).

Manages chronic graft versus host disease (cGVHD).

Prescribed off-label to diffuse large B-cell lymphoma (DLBCL).

6. Stelara

Stelara is a highly effective medication that contains ustekinumab. Ustekinumab is a monoclonal antibody derived from immune system cells. It is specifically designed to target and alleviate the symptoms of various inflammatory conditions associated with immune system dysfunction.

Uses

Provides relief for people suffering from this autoimmune skin condition.

Treats psoriatic arthritis for adults.

Deals with the challenges of moderate to severe Crohn's disease.

Treats adults with this type of inflammatory bowel disease.

Used off-label in the treatment of active systemic lupus erythematosus.

Used for investigational purposes of hidradenitis suppurativa.

7. Xarelto

Xarelto (rivaroxaban) is a medication also classified as a blood thinner. It works by inhibiting the activity of Factor Xa, an enzyme involved in blood clot formation. While Xarelto does not thin the blood, it helps prevent the formation of blood clots and reduces the risk of strokes and systemic embolisms in certain medical conditions.

Uses

Reduces the risk of stroke and systemic embolism with nonvalvular atrial fibrillation.

Treats and maintains drugs for deep vein thrombosis (DVT).

Reduces the risk of recurrence of pulmonary embolism.

Prevents blood clot formation in patients suffering from heart failure, respiratory disease, or infectious diseases.

Used as a prophylactic treatment to prevent blood clots in patients with cancer.

Prevents the recurrence of ischemic events, such as heart attacks or peripheral artery disease

8. Opdivo

Opdivo is an immunotherapy drug that belongs to a class of medications known as checkpoint inhibitors. It targets the PD-1 receptor, found on the surface of T cells, the immune cells responsible for fighting cancer. PD-1 helps regulate immune responses in healthy tissues, but cancer cells can exploit this mechanism to evade immune attacks. Opdivo blocks the interaction between PD-1 and PD-L1/PD-L2 molecules in cancer cells. This blockage enables T cells to recognize and destroy cancer cells effectively.

Uses

Treats advanced melanoma.

Treats non-small cell lung cancer.

Used in combination with ipilimumab for newly diagnosed malignant pleural mesothelioma.

Treats adult patients with classical Hodgkin lymphoma.

Treats patients with recurrent or metastatic head and neck squamous cell carcinoma.

Treats with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colon.

Factors that Impact the Demand for the Drugs

Here are four key factors that impact the demand for drugs:

1. Disease Prevalence and Epidemiology

The prevalence of diseases and their impact on the population greatly influence the demand for drugs. The burden of chronic diseases, or infectious outbreaks, shapes the market for specific medications to treat and manage these conditions.

2. Demographic Changes

Changing demographics, such as aging populations and urbanization, play a crucial role in drug demand. Different age groups have varying healthcare needs, and understanding demographic shifts helps target drug development and delivery strategies accordingly.

3. Economic Factors

Economic factors, including income levels, affordability, and healthcare expenditures, substantially impact drug demand. If medicines are expensive or not affordable, people may struggle to access their prescribed treatments. The cost and accessibility of medications greatly affect the choices people make and their ability to follow through with the necessary treatments.

4. Government Policies and Regulations

Regulatory frameworks, pricing regulations, reimbursement policies, and intellectual property rights all affect the availability, accessibility, and affordability of medicines. This further influences its demand in the market. Understanding and navigating these factors is crucial for ensuring that drugs are accessible and affordable to those who need them.

The Bottom Line

In conclusion, understanding the demand for drugs in India is vital for pharmaceutical companies, policymakers, and healthcare providers. By now, you must be aware of the factors that significantly impact drug demand. By aligning their strategies with these factors, stakeholders can meet the evolving healthcare needs of the Indian market effectively.

Moreover, if you're looking for a trusted name in the pharmaceutical industry for reliable and high-quality medications, consider Mediwin Pharmaceuticals. They have been one of the top pharma companies serving India since 1990. It is among the top pharmaceutical manufacturing companies in Ahmedabad because they facilitate effective medications for chronic conditions, specialized therapies, and preventive care.

So, visit Mediwin’s website today to discover its diverse product portfolio!

Source link

[mcatmemoranda]

One of my pts has ankylosing spondylitis. He said he used to be treated for his symptoms with prednisone 20 mg, which was then tapered*. The treatment is NSAIDs. If that doesn't work, you can add a disease modifying antirheumatic drug (DMARD). Tx is basically: NSAIDs, DMARDS, PT, smoking cessation.

*According to UpToDate: In patients with axial SpA, there is an extremely limited role, if any, for the use of opioid analgesics. Systemic glucocorticoids (eg, prednisone) are ineffective for axial SpA in low to moderate doses and are not indicated. However, the pt can't take NSAIDs because he has kidney disease. So that makes sense. This is complex. I was reading through notes from his office visits. Some physicians think of and pick up things that others don't; but the diagnostic tests chosen are not the gold standard. So it just shows that nobody knows everything and it takes a team to take care of the pt. I care about this pt and have good rapport with him, so I want to help him feel good and be healthy.

From UpToDate:

The primary goals of management are to optimize short- and long-term health-related quality of life through relief of symptoms, maintenance of function, prevention of spinal complications, minimization of extraspinal and extraarticular manifestations and comorbidities, and maintenance of effective psychosocial functioning. Most patients benefit from care by an expert in rheumatologic disease, such as a rheumatologist; care should be coordinated with appropriate specialists, depending upon the clinical features; and active patient engagement in shared decision-making with their clinical team is an important element of care.

All patients with axial spondyloarthritis (SpA) should receive education about their disease and its management; counseling regarding smoking cessation, depression screening and psychosocial support, and physical therapy with instruction in home exercises.

In most patients with symptomatic axial SpA, we recommend a nonsteroidal antiinflammatory drug (NSAID) as initial therapy, rather than starting a disease-modifying antirheumatic drug (DMARD). Examples include naproxen (up to 500 mg twice daily) or ibuprofen (up to 800 mg three times daily), although any NSAID may be effective (table 1). Regardless of the NSAID used, the maximum dose is usually required, and the response should be assessed after a sustained dose on a daily basis for at least two to four weeks. In patients with an inadequate response, we switch to a second NSAID.

In patients with symptoms due to active axial SpA and an inadequate response to initial therapy with at least two NSAIDs consecutively, we suggest adding a tumor necrosis factor (TNF)-alpha inhibitor rather than treatment with NSAIDs alone. Any of the TNF inhibitors (eg, subcutaneous adalimumab 40 mg every other week or infliximab 5 mg/kg by intravenous infusion at zero, two, and six weeks followed by a maintenance dose of 5 mg/kg every eight weeks) is an acceptable option; the choice between drugs is based upon patient preferences regarding the route and frequency of administration, physician preference and experience, and regulatory and cost constraints. These biologics do not need to be used together with a conventional synthetic (cs) immunosuppressive agent such as methotrexate (MTX).

I'm assuming a rheumatologist would manage DMARD if the pt needs it.

The interleukin 17 (IL-17) inhibitors secukinumab and ixekizumab are reasonable alternatives to a TNF inhibitor as initial biologic therapy (for example, in case of concomitant psoriasis), although there is much more experience and evidence of long-term efficacy and safety with the TNF inhibitors.

[biogenericpublishers]

Latent Crohn’s Disease Uncovered During Treatment with Secukinumab in a Patient with Ankylosing Spondilitis by Moșteanu Elena Ofelia* in Open Access Journal of Biogeneric Science and Research

Keywords: Crohn’s disease, IL-17A Inhibitors, Secukinumab

Introduction

The inflammatory bowel diseases (IBD) are defined as a group of heterogeneous disorders with multifactorial etiology, in which a chronic inflammation of the digestive tract is caused by disturbances in the immune response to the pathogenic low-diversity gut microbiota [1]. IBD includes two major entities: Crohn’s disease (CD) and Ulcerative Colitis (UC). Current data estimates an impressive prevalence of over 0.3% globally [2]. CD is defined as transmural inflammation of any part of the gastrointestinal tract (GTI), from mouth to the perianal area, with a mainly ileal localization, while UC is an autolimited disease, of localization and histology, affecting only the colorectal mucosa. The clinical presentation of CD typically includes non-specific symptoms as abdominal pain, diarrhea, low-grade fever and weightloss, and with a low prevalence, extraintestinal manifestations. Complications of the disease include stricturing with secondary bowel obstruction, penetrating fistulas or abcesses.

Ankylosing spondylitis (AS) is a disease of spondyloarthropathies’ (SpA) class, which includes arthritis of different etiology. AS is a chronic inflammatory rheumatic disease involving primarily the axial skeleton, clinically expressed by back pain. It’s progressive character leads to continuosly increasing stiffnes of the spine, leading to spine fusion in late stages. In the light of epidemiologic studies of SpA associated with IBD, it was found an association of these pathologies in a third of the patients [3,4]. The overexpression and the complex immunoregulation of IL-17/IL-23 axis is of main importance in the interconnection of these entities [5]. Secukinumab is a human monoclonal antibody, a IL-17A inhibitor that was approved on the market in 2015, 20 years after Th-17, and consequently IL-17, was discovered. The novelty of the current case report is the long-term follow-up of a patient with new-onset of CD during treatment with Secukinumab, describing the resolution of the newly-emerged disease.

Case Report

We present the case of a 40 years old male, smoker, diagnosed with AS in 2006, for which he was treated with sulphasalazine for 4 years, etoricoxib for the next 2 years and etanercept (a TNFα inhibitor) for 7 years, until 2019, when the treatment with Secukinumab started. In 2016, he started having brief episodes of mesogastric abdominal pain, nausea, diarheea, episodes that didn’t remit with any medication, but did spontaneuosly after aproximately 24 hours. Because of the short duration and the low frequency, one episode every 6 months, the patient was not referred. After only 2 weeks of treatment with Secukinumab, in February 2019, these episodes worsened and became more frequent, almost weekly at the moment of the first gastrointestinal assessment in April. The abdominal ultrasound and the colonoscopy didn’t reveal any pathologic modifications. The symptoms were to be controlled by diet. In November, the patient was admitted again as the symptomatology worsened. Physical evaluation revealed pain at the abdomnial palpation in the right flank. Paraclinical examination show only an elevated C-reactive Protein of 2.88 mg/dl. Stool examination excluded any gastrointestinal infection. Abdominal ultrasound was nomal. A colonoscopy was performed and revealed cecal pseudopolyps, but the terminal ileon could not be inspected. The MRI Enterography revealed an ileal inflammatory stenosis, right next to the ileocecal valve, explaining the impossibility of ileocecal valve intubation (Figures 1&2).

The diagnosis was of ileocecal CD due to the inflammatory stenosis with subsequent upstream bowel dilatation (Figure 3). Secukinumab administration was discontinued and treatment with Adalimumab was indicated. At 3-months follow-up, the patient’s gastrointestinal symptomatology completely remmited, the remission being controlled by maintaining the treatment with Adalimumab, daily administration of inulin and simeticone and diet.

Discussion

It is widely known that there is a close association between IBD and SpA in terms of genetics, microbiota and immunology discorders [3,4]. In the etiopatogenesis of IBD, CD4 Th cells play a major role by starting and maintaining the autoimmune inflammation of the gastrointestinal tract, by producing pro-inflammatory cytokines. Beside CD4 Th cells, another subset of Th cells, Th17 cells, are overexpressed at this level and are positively regulated by IL-23, another proinflammatory cytokine produced by antigen-presenting cells, after the contact with the compounds of the pathological microbiota [6]. The activation of IL-17/IL-23 axis is fundamentally connected to the etiology of both CD and AS, IL-17 being found extensively in the blood, the synovial fluid in AS and in the intestinal lamina propria of CD patients [7,8].

Human interleukin IL-17 was found to be involved in different autoimmune diseases, such as systemic sclerosis, multiple sclerosis, systemic lupus erythematosus, psoriasis, asthma, SpAs and IBD [9-14]. While IL-17 is a pro-inflammatory cytokine, current data suggests a protective role on the gastrointestinal tract in IBD patients [15]. The importance of this paradox is to be seen in patients that benefit of biological treatment with IL-17 inhibitors and might associate a latent IBD.

Studies conducted with the objective of administering Secukinumab on CD animal models studies (2 ref trial) and on one human trial, which had to be completed prematurely because of the diseases’ unfavorable evolution compared to placebo, enforcing so the theory of IL-17 as being, in an unknown manner, a protective factor in the natural inflammatory evolution of CD. It is suggested that this difference may be due to the pathological microbiota found in IBD [16-18]. Using the data of these trials and knowing the statistical association between CD and SpA, the IL-17 molecule being overexpressed and playing different roles in both diseases, it might come handy that by inhibiting the IL-17/IL-23 path in SpA, the inflammation of the gut might worsen.

In Secukinumab’s summary of product characteristics, IBDs are mentioned in the section of special warnings and precautions for use, warning that the patients should be closely monitored. The latest retrospective analysis of pooled data from 21 clinical trials, containing 7355 patients, concluded that the cases of IBD during treatment with Secukinumab were uncommon [19]. The reported incidence of CD among 794 patients treated for SpA was 0,1 per 100 patients/year, with 5 new onset cases of CD (0,63%) and an exacerbation found in 3 out of 5 patients with a history of CD. The question this case raised was whether our patient was having a silent CD that was activated by this treatment or he developed the disease on a normal gastrointestinal tract. Anamnestically, the patient did associate in time the onset of gastrointestinal manifestations with the use of Secukinumab.

Diarrhea is a common side effect of this treatment and the patients should be informed of the possibility of having an inactive IBD that might activate during this treatment and they should be advised to adress a specialist if the gastrointestinal symptoms persist. IL-17 positive cells are not detected in the mucosa of healthy individuals, infectious colitis or ischaemic colitis patients, but IL-17 levels are significantly elevated in active and even in inactive CD [20]. Therefore, we can’t state that a subclinical CD was not present, taking into consideration also the frequency of IBD and SpA associating. Using the patient’s history and the current data available in the literature, we strongly believe that Secukinumab was the trigger of CD in this case.

Currently there are treatment guidelines just for IBD and SpA individually, but not any for both IBD and SpA, which would be needed in the near future, as more specific biological therapies emerge, targeting different inflammatory pathways. As written in the summary of product characteristics of Secukinumab, a close follow-up for IBD patients is needed, but, even if the new onset of CD is reported to have a low incidence, a gastroenterological monitoring would be recommended even for healthy individuals, because of the reported prevalence of IBD and SpA association.

Conclusion

A gastroenterological consult before the initiation of the treatment would be beneficial, since SpA may precede the onset of IBD [21,22] or may associate with an underlying asymptomatic intestinal inflammation [23]. This case report is also enforcing the current data of IL-17 having a protective role in IBD, it’s path inhibition leading to exacerbation or to activation of a silent IBD. Of biological therapies, there are safer treatment schemes for a patient with AS and symptomatic or silent CD, which could include Ustekinumab, a human monoclonal antibody that is targeting the IL-12/IL-23 path, Infliximab, a chimeric monoclonal antibody that inhibits tumor necrosis factor alpha (TNFα) or Adalimumab, the first human monoclonal antibody that bind and neutralizez TNFα. The statistics and this case report are underlining the importance of a multi-disciplinary approach when prescribing biological therapy, including rheumatologists and gastroenterologists. Why the IL-17/IL-23 axis is having a „paradoxal” role on the gastrointestinal tract it still a question that’s laking an answer and represents a future research direction.

More information regarding this Article visit: OAJBGSR

https://biogenericpublishers.com/pdf/JBGSR.MS.ID.00156.pdf https://biogenericpublishers.com/jbgsr.ms.id.00156.text/

For more open access journals click on https://biogenericpublishers.com/

[aditi3019]

Global Biosimilars Market 2020: Historical Analysis, Business Opportunities, Latest Innovations, Top Players and Forecast

Biosimilars Market Synopsis  

Market Research Future (MRFR) postulates that the global biosimilars market share is predicted to garner USD 3.35 billion, grabbing a CAGR of 26% throughout the forecast period (2017-2023). The augmenting incidences of several chronic diseases are estimated to favor the Biosimilars Market Growth. Biosimilars are referred to as a biological medical product which are identical copies of the original medical product. They are generally derived from a plant, bacteria, yeast, and other several processes. Biosimilars are neither generics nor treated like generic drugs. Also acknowledged as bio-pharmaceuticals, biosimilars differ from generics in the manufacturing process. They are produced by two main processes, recombinant DNA technology and controlled gene expression.  

Biosimilars Market Potential and Pitfalls  

With the augmenting incidences of several chronic diseases, growing demand for cheap medical products, and strategic collaborations leading to clinical trials and enhanced productivity, the global biosimilars market is estimated to flourish throughout the appraisal period. Biosimilars are extensively used in the treatment and prevention of chronic diseases like cancer, diabetes, autoimmune disease, cardiovascular diseases (CVDs), kidney failure, rheumatoid arthritis, hematological disease, hormone growth deficiency, and infectious disease. This is likely to create momentum to the market growth during the estimated period. Also, with the growth in the geriatric population, the demand for biosimilars is expected to trigger.  

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/1329  

Biosimilars are constantly gaining prominence over other conventional biologics due to lesser cost as compared to the parent biological drugs. Moreover, different private and government bodies are promoting the use of biosimilars over synthetic drugs and conventional biologics, which is further propelling the growth of the market across the globe. Also, with the rapid growth in the pharmaceutical sector combined with the high cost of existing biological drugs, the market is anticipated to boom.  

On the contrary, physician skepticism coupled with the lack of awareness regarding biosimilars is some of the top barriers likely to vitiate the market growth in the coming years. Additionally, complexity and high manufacturing cost can act as roadblocks to the mainstream production of biosimilars. Despite such hiccups, discounted prices of biosimilars will impact the overall biosimilar sales, as patients are the key beneficiaries.  

Global Biosimilars Market: Segmental Analysis  

The global biosimilars market has been segmented on the basis of product, application, and manufacturing.  

By mode of product, the global biosimilars market has been segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and others. Among these, the recombinant glycosylated proteins segment is anticipated to occupy the largest share and is likely to retain its dominance. The growth is credited to the wide therapeutic area of such proteins coupled with the presence biosimilar version of monoclonal antibodies at much lower rates.  

By mode of application, the global biosimilars market has been segmented into oncology, immune diseases, blood-related disorders, and others.  

By mode of manufacturing, the global biosimilars market has been segmented into contract manufacturing and in-house manufacturing. Among these, the in-house manufacturing is presumed to occupy the largest share owing to the rising demand for cost-effective biosimilar products due to the augmenting incidences of several chronic diseases.  

Biosimilars Market Regional Insights  

Geographically, the biosimilars market span across regions namely, Europe, Asia Pacific, North America, and the Middle East & Africa.  

Among all the regions, the European region is likely to dominate the global biosimilars market and is estimated to retain its dominance in the coming years. The growth is credited to the rising prevalence of diseases coupled with the growth in the geriatric population in this region. Moreover, advanced medical research and technological advancements are further triggering the demand for biosimilars in this region. The growth in the regional market is likely to be stimulated by patent expiry of biologic products combined with the launch of new biosimilars and the advent of new market participants.  

The North American region is predicted to occupy the second largest share in the global market owing to technological advancements and extensive medical research. The market is mainly driven by the presence of large research labs such as Amgen, Sandoz, Teva Pharmaceutical, and others.  

The Asia Pacific region is anticipated to emerge as the fastest-growing region owing to the immense economic development coupled with the booming biotechnology companies in this region. The country-specific markets in this region generating maximum revenue are India, Australia, South Korea, Japan, and China.  

Biosimilars Industry Updates  

February 19, 2019: Sandoz, a developer of biosimilar has recently announced the launch of their biosimilar adalimumab, Hyrimoz, in Spain. This biosimilar, referencing Humira, was authorized in the European Union for sale in July 2018. It has been approved for indications of reference adalimumab and is available in 40 mg doses for subcutaneous injection in pre-filled pen or a syringe form.  

Obtain Premium Research Report Details @ https://www.marketresearchfuture.com/reports/biosimilars-market-1329  

Biosimilars Market Competitive Dashboard  

The prominent players operating the global biosimilars market are Biocon Ltd. (India), Eli Lilly (U.S.), Novartis (Switzerland), Celltrion Inc. (South Korea), Dr. Reddy’s Laboratories Ltd. (India), Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Sandoz International GmbH (Germany), Astra Zeneca (U.K.), Amgen Inc. (U.S.), Samsung Bioepis (South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), and Accord Healthcare (U.K.).  

[pediadoc7-blog]

Adalimumab Drug Information

Medical information for Adalimumab including Indication, Dosing, Adverse Effect. To know more about Adalimumab Drug read this article https://www.pediatriconcall.com/drugs/adalimumab/224

[insightaceanalaytic-blog]

GLOBAL  ADALIMUMAB BIOSIMILAR  MARKET

InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on Global Adalimumab Biosimilar Market  Assessment – Revenue Forecast (Value & Volume), Installed Base, Historic Revenue and Forecast Till 2027 Adalimumab is a first humanized monoclonal antibody indicated for the treatment of various autoimmune diseases. Adalimumab is an anti-TNF (tumour necrosis factor) drug that block the action of TNF (tumour necrosis factor)to reduce the inflammation. It is prescribed for the treatment of diseases such as rheumatoid arthritis,ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and psoriasis. It was first discovered by “phage display” technique which was named D2E7. Furthermore, it experienced the various manufacturing process at BASF Bioresearch Corporation and developed by BASF Knoll. In December 2000, Abbott announced the acquisition of BASF Bioresearch Corporation. In January 2013, Abbott Laboratories separated its pharma business named as AbbVie Inc. which was further involved in development and commercializing activities. AbbVie marketed Adalimumab product under the trade name of Humira. It was approved by U.S. Food Drug and Administration (FDA) in 2008 and by European Medicines Agency in 2003.

[drjatinderjuneja]

Rheumatoid Arthritis Affecting Your Movement?

What is it

Rheumatoid arthritis is a chronic and degenerative disease that is characterized by causing inflammation of the synovial membrane (membrane that nourishes, protects and covers the cartilage) of the joints and surrounding tissues. Sometimes arthritis can have an extra-articular behavior and damage organs and systems such as the heart, kidney and lung. For this reason, rheumatologist in Delhi describe it as a systemic disease.

The inflammation of this membrane is responsible for the pain, the clearly visible swelling, the sensation of stiffness that patients can feel in the mornings and the loss of joint mobility.

According to the best rheumatologist in Delhi, it affects joints more intensely than others, mainly the more mobile ones such as the hands and feet, the elbows, the shoulders, the hips, the knees and the ankles. There are some that are never affected.

If the swelling remains in a sustained and not controlled can end up damaging the bones, the ligaments and the tendons there around the joint. This can cause a progressive deformity of the joints and the loss of the ability to perform daily movements and tasks. All this affects the quality of life of patients, says top rheumatologist in Delhi.

Incidence

According to arthritis specialist in Delhi, it is estimated that worldwide this pathology affects between 0.5 and 0.8 percent of the population, that is, approximately five people per thousand worldwide. However, there are still many people who are not diagnosed.

According to arthritis doctor in Delhi, in India there are more than 1,000,000 people with rheumatoid arthritis and each year 20,000 new cases are diagnosed. "This is a remarkable figure because rheumatoid arthritis is the most disabling of rheumatic diseases," best arthritis specialist in Delhi explains.

Its incidence is greater in women than in men. In fact, for every 3 diagnoses in women, only one is performed in men. Although it can affect any person and appear at any age, it usually manifests itself more frequently in women from 30 to 50 years old.

Within the same geographical area there is a tendency to greater occurrence in urban versus rural areas.

Causes

The cause of the onset of this disease is unknown. Infectious agents such as bacteria or viruses have been studied and, although suggestive data have been found in some cases, there is still no evidence to confirm their involvement.

Rheumatologist in Delhi believes that it may have a genetic origin since the immune system attacks the joints because they do not recognize them as their own and therefore become inflamed. What is known as autoimmune disease. Likewise, it is believed that certain proteins that are transmitted in a hereditary way could predispose to the disease.

The differences in the frequency of the disease make the arthritis specialist in Delhi also suggests that there are environmental factors that intervene in the onset of the disease.

Symptom

As indicated by the best rheumatologist in Delhi, the disease begins slowly and insidiously with general manifestations that present other diseases, such as fever or asthenia.

However, the main symptom of this disease is the involvement of the diarthrodial joints. Initially there is an inflammation that is noticeable to the naked eye and causes pain in the individual who suffers. Along with inflammation, other manifestations may appear, such as increased volume, stiffness after night time rest that gradually disappears as the patient exercises daily activity, muscle weakness and limited mobility.

Also, hard lumps (rheumatoid nodules) may appear in areas of skin friction such as the elbows, the back of the fingers and toes, which can also be located inside the body.

If the disease is at an advanced stage, the patient may have some deformity due to the progressive deterioration of the affected joints. In addition, it can evolve and affect vital organs such as the kidney or lung.

It often causes dryness of the skin and mucous membranes. This causes inflammation and subsequent atrophy of the glands that generate tears, saliva, digestive juices or vaginal discharge (Sjögren's syndrome).

It can also cause some fever and, sometimes, inflammation of the blood vessels (vasculitis), which causes nerve injuries or sores on the legs (ulcers). Other symptoms are inflammation of the membranes lining the lungs (pleuritis) or the envelope of the heart (pericarditis), or inflammation and scarring of the lungs can cause chest pain, difficulty breathing and abnormal heart function.

"In the long term, the consequences of the disease left to its evolution are the limitation and incapacity for the realization, initially, of the work activities and, later, of the daily life of the subject who suffers it.

Prevention

Currently there is no measure to help prevent the onset of rheumatoid arthritis. However, Joint pain specialist in Delhi recommends regular physical activity to promote the use of all joints.

In addition, once rheumatoid arthritis has been diagnosed, they recommend following arthritis treatment in Delhi appropriately to prevent the progression of the disease.

Diagnosis

Although there are no specific tests, the diagnosis of this pathology is relatively simple if the patient goes to the rheumatologist on suspicion of having some of the symptoms already described.

If the disease is in an initial phase, the diagnosis can be more complicated since all the symptoms may not appear in the laboratory tests, since the assessment of the disease is mainly clinical. "It is done in the presence of a series of signs and symptoms in the joints in the form of polyarthritis (arthritis of multiple joints) of symmetrical nature), chronic course (more than 6 weeks) and with practically constant involvement of hand joints", specify by top rheumatologist in Delhi.

The problem in diagnosing it is that there are other rheumatic diseases, such as lupus or psoriatic arthritis that in the early stages can be confused with rheumatoid arthritis.

During the evaluation, the rheumatologist in Delhi can perform a series of complementary examinations to facilitate the diagnosis:

Blood test.

Rheumatoid factor tests.

Test to detect antibodies against citrullinated peptides. These antibodies are present in two thirds of patients with this condition.

X-rays to detect the presence of erosions.

Treatments

Rheumatoid arthritis is a chronic disease that currently has no treatment to cure the disease. However, pharmacological therapies and treatment strategies are very effective and allow good control of the disease.

The best arthritis treatment in Delhi includes two types of drugs: those used to relieve pain (anti-inflammatories and corticosteroids), and those that serve to modify the disease in the long term. The latter can be effective weeks or even months after treatment. They are not effective in one hundred percent of patients, according to arthritis specialist in Delhi, so the doctor usually prescribes several sequentially to find one that is more effective and better tolerated by the patient.

The mainstay of the therapy is the antirheumatic drugs that modify the disease (Fames). Among them, the most used is methotrexate. Other drugs would be sulfasalazine, leflunomide or gold salts (now disused).

According to the arthritis doctor in Delhi, the early prescription of these treatments is essential to reduce to the maximum the joint inflammation and the progression of the disease.

In cases where the Fames do not work properly, the joint pain specialist in Delhi treats the pathology with biological therapies. These are drugs designed with complex formulas that include the TNF antagonists (etanercept, adalimumab and infliximab), abatacept and rituximab. These drugs have been shown to be very effective in improving pain and inflammation and in preventing joint destruction.

Both biological therapies and Fames can have side effects, but in general they are quite safe and patients tolerate them well.

If the disease is very advanced, the patient may need surgery.

Other data

Relationship with tobacco

Numerous studies have shown that there is an association between tobacco consumption and the development of the disease. However, best arthritis specialist in Delhi indicates that the causal relationship between smoking and the development of pathology is complex.

On the other hand, studies have also shown that patients who smoke suffer from the disease more severely than those who are not smokers.

Forecast

The prognosis of the disease is very variable, since in some cases there are benign diseases that can be controlled with a simple treatment and others in which the disease evolves very quickly and the prognosis is fatal in a short time.

If joint pain treatment in Delhi is not done properly, it is usual for the disease to evolve towards irreversible joint destruction with a deterioration of the important lung capacity. This prognosis varies if it is approached with the optimal treatment.

In addition, there are risk factors that worsen the prognosis: the onset of the disease at young ages, smoking, the existence of citrullinated antiprotein antibodies or rheumatoid factor or the involvement of other organs, for example.

Living with the disease

The first step that a person diagnosed with rheumatoid arthritis should take to adapt to their illness is to avoid a hectic life, sudden movements and try to sleep an average of 10 hours.

In addition, it is advisable that these patients avoid those jobs that require intense physical exercise. During the workday, they should maintain a straight position in the seat and avoid remaining with the neck or back flexed for a long time. Also, during the rest it is convenient to maintain a proper posture, avoid bending the joints and keep the arms and legs stretched.

Regarding footwear, arthritis specialist in Delhi advises that it be elastic, firm and leather. The heel should be attached, the wide toe and the instep high enough so that chafing does not occur.

The obesity can cause an overload on joints, therefore, try to lead a healthy and balanced diet and avoid gaining weight.

[minbiotch]

What is adalimumab? What conditions is adalimumab suitable for?

Adalimumab (Humira) is a self-injectable biotherapeutic drug. It has been approved by the State Food and Drug Administration (CFDA) for two indications, namely rheumatoid arthritis and ankylosing spine. inflammation.

In 2013, through the study of adverse events in clinical trials of adalimumab for various indications in the past 12 years, no new adverse reaction safety signals beyond previous experience were found. In adalimumab-treated patients, the overall malignancy incidence was as expected in the general population. This drug is usually used alone or in combination with methotrexate.

Adalimumab has been approved for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, and Crohn's disease in the United States and the European Union. To a large extent relieve the patient's symptoms. The launch of adalimumab in China brings a new dawn to the treatment of rheumatoid arthritis patients in China and opens a new era of rheumatoid immune disease treatment.

Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by symmetry, multiple joints, and small joints. It is known as "immortal cancer". The immune system of the patient will destroy healthy joints and cause joint damage. Pain, swelling, stiffness, symptoms of fatigue and weakness, late stiffness and deformity, severely impaired function, and ultimately loss of joint function.

Humira in combination with methotrexate for the treatment of Adult patients with moderately to severely active rheumatoid arthritis who have not responded well to disease-modifying antirheumatic drugs (DMARDs), including methotrexate. The combination of Humira and methotrexate slowed the progression of joint damage (shown on X-rays) and improved physical function. Compared with traditional drugs, these drugs have strong and long-lasting efficacy, can effectively relieve disease symptoms, imaging progress, and functional level, and have good safety, and are suitable for various rheumatoid arthritis patients.

Ankylosing spondylitis

Ankylosing spondylitis (AS) is a disease characterized by inflammation of the sacroiliac joints and spinal attachment points. Strong association with HLA-B27. Certain microorganisms, such as Klebsiella, share antigens with susceptible individuals' own tissues, which can trigger abnormal immune responses. Ankylosing spondylitis is a chronic inflammatory disease characterized by fibrosis and ossification of the large joints of the limbs, as well as the annulus fibrosus of the intervertebral disc and its adjacent connective tissue, as well as joint stiffness.

Humira is used in adult patients with severe active ankylosing spondylitis who have not responded well to conventional therapy. It has the characteristics of fast onset and good curative effect. The condition of most patients can be rapidly and significantly improved, such as morning stiffness, low back pain, peripheral arthritis, tendonitis, chest expansion, ESR and CRP, etc. After a period of application, the patient's physical function and health-related quality of life Significant improvement, in particular, can restore some newly emerged spinal mobility dysfunction.

Minbiotech is a adalimumabb manufacturer and adalimumabb factory, Minbiotech CAS:331731-18-1, adalimumabb supplier, Welcome to visit our website.

Related news of Minbiotech bio-pharmacy

Maytansinol properties, uses and production process Maytansinol is the common pa

Specific contraindications for the use of Simorox tablets

[industry365]

Eclinical Solutions Market Is Expected To Reach New Growth Revenues During 2021-2028

Polaris Market Research assumes that with the expected launch of the potential promising therapies, the market is anticipated to expand in both psoriasis and atopic dermatitis segments. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is due to the increased adoption of high priced biologics. Despite the launch and availability of multiple biologics, only 10% of the patients have access to these treatments and the market continues to remain underpenetrated.

Currently, the dermatology drugs market is highly fragmented but offer several commercial opportunities. There remains significant unmet need for safer and cost-effective treatment options. Psoriasis market was nearly USD 6 billion markets in 2016 due to the existing effective TNF alpha treatments. In Acne, retinoids and antibiotics are the mainstay treatments but what makes this indication lucrative is the promising candidates in the pipeline including Foamix’s FMX-101 and Dermira’s DRM-101.

Download sample https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/request-for-sample

Polaris Market Research has provided the forecasts of the Global Dermatology Drugs Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:

Market Analysis by Dermatology Key Indications

Market Analysis by Treatment Class/Marketed Drugs

Market Analysis by Regions

The Marketed Therapies undertaken in forecast from 2016-2022 are:

etanercept; Enbrel

infliximab; Remicade

adalimumab; Humira

ustekinumab; Stelara

secukinumab; Cosentyx

ixekizumab; Taltz

golimumab; Simponi

brodalumab; Siliq

guselkamab; Tremfya

Topical Drugs

Oral Antibiotics

The Major Indications in Dermatology Therapy area:

Atopic Dermatitis

Psoriasis

Acne

Rosacea

Leading Companies investigated in the Report are:

Allergan Plc

Valeant Pharmaceuticals

Dermira Inc

Aclaris Therapeutics, Inc

AnaptysBio, Inc

Revance Therapeutics

Foamix Pharmaceuticals

Novan, Inc

Sienna Biopharmaceuticals

Pfizer

Sanofi

Galderma

Leo Pharma

Roviant Sciences

Otsuka Pharmaceuticals

Get Discount offer: https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/request-for-discount-pricing

[newsupdate-1]

Dermatology Drugs Market Size, Growth, Emerging Trends And Forecast

Polaris Market Research assumes that with the expected launch of the potential promising therapies, the market is anticipated to expand in both psoriasis and atopic dermatitis segments. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is due to the increased adoption of high priced biologics. Despite the launch and availability of multiple biologics, only 10% of the patients have access to these treatments and the market continues to remain underpenetrated.

Currently, the dermatology drugs market is highly fragmented but offer several commercial opportunities. There remains significant unmet need for safer and cost-effective treatment options. Psoriasis market was nearly USD 6 billion markets in 2016 due to the existing effective TNF alpha treatments. In Acne, retinoids and antibiotics are the mainstay treatments but what makes this indication lucrative is the promising candidates in the pipeline including Foamix’s FMX-101 and Dermira’s DRM-101.

Get sample copy of this report : https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/request-for-sample

Polaris Market Research has provided the forecasts of the Global Dermatology Drugs Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:

·         Market Analysis by Dermatology Key Indications

·         Market Analysis by Treatment Class/Marketed Drugs

·         Market Analysis by Regions

The Marketed Therapies undertaken in forecast from 2016-2022 are:

·         etanercept; Enbrel

·         infliximab; Remicade

·         adalimumab; Humira

·         ustekinumab; Stelara

·         secukinumab; Cosentyx

·         ixekizumab; Taltz

·         golimumab; Simponi

·         brodalumab; Siliq

·         guselkamab; Tremfya

·         Topical Drugs

·         Oral Antibiotics

The Major Indications in Dermatology Therapy area:

·         Atopic Dermatitis

·         Psoriasis

·         Acne

·         Rosacea

Leading Companies investigated in the Report are:

·         Allergan Plc

·         Valeant Pharmaceuticals

·         Dermira Inc

·         Aclaris Therapeutics, Inc

·         AnaptysBio, Inc

·         Revance Therapeutics

·         Foamix Pharmaceuticals

·         Novan, Inc

·         Sienna Biopharmaceuticals

·         Pfizer

·         Sanofi

·         Galderma

·         Leo Pharma

·         Roviant Sciences

·         Otsuka Pharmaceuticals

Request For Discount : https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com

[udaycmi]

Dermatology Drugs Market 2021 Future Growth Analysis and Challenges

Polaris Market Research assumes that with the expected launch of the potential promising therapies, the market is anticipated to expand in both psoriasis and atopic dermatitis segments. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is due to the increased adoption of high priced biologics. Despite the launch and availability of multiple biologics, only 10% of the patients have access to these treatments and the market continues to remain underpenetrated.

Currently, the dermatology drugs market is highly fragmented but offer several commercial opportunities. There remains significant unmet need for safer and cost-effective treatment options. Psoriasis market was nearly USD 6 billion markets in 2016 due to the existing effective TNF alpha treatments. In Acne, retinoids and antibiotics are the mainstay treatments but what makes this indication lucrative is the promising candidates in the pipeline including Foamix’s FMX-101 and Dermira’s DRM-101.

Get sample copy of this report : https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/request-for-sample

Polaris Market Research has provided the forecasts of the Global Dermatology Drugs Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:

·         Market Analysis by Dermatology Key Indications

·         Market Analysis by Treatment Class/Marketed Drugs

·         Market Analysis by Regions

The Marketed Therapies undertaken in forecast from 2016-2022 are:

·         etanercept; Enbrel

·         infliximab; Remicade

·         adalimumab; Humira

·         ustekinumab; Stelara

·         secukinumab; Cosentyx

·         ixekizumab; Taltz

·         golimumab; Simponi

·         brodalumab; Siliq

·         guselkamab; Tremfya

·         Topical Drugs

·         Oral Antibiotics

The Major Indications in Dermatology Therapy area:

·         Atopic Dermatitis

·         Psoriasis

·         Acne

·         Rosacea

Leading Companies investigated in the Report are:

·         Allergan Plc

·         Valeant Pharmaceuticals

·         Dermira Inc

·         Aclaris Therapeutics, Inc

·         AnaptysBio, Inc

·         Revance Therapeutics

·         Foamix Pharmaceuticals

·         Novan, Inc

·         Sienna Biopharmaceuticals

·         Pfizer

·         Sanofi

·         Galderma

·         Leo Pharma

·         Roviant Sciences

·         Otsuka Pharmaceuticals

Request For Discount : https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com

[glamyohealthdelhi]

Glamyo Healthcare – Best Anal Fistula Laser Treatment in Delhi

An Anal fistula is a path or tunnel from the inside of the anus to the outside part (skin) close to the anus where the waste is released. The abscess is normally generated near anus in the skin, and very small waste (pus) is subsequently stored and discharged.

In the anus wall there are a number of small glands which make mucus. The waste can sometimes block the glands and infect them. The infected part attempts to release itself and makes its own tunnel to the outside skin from the inside anus of the soft tissue. And the abscess is formed in the outer skin. Depending on the soft tissues, fistula dimensions may vary. The abscess is not automatically cured. It continues to come and go. you will need a doctor to repair the fistula, and the only option is surgery.

Diagnosis:

Fistulas are normally easy to find because the fistula is in the outer skin. However, some are hard to find. Sometimes they heal by themselves and open again later. The doctor will usually examine it physically. He/she might need to put his finger inside the anus and find the path. You might also need to perform an x-ray procedure called a fistulogram in order to detect the exact fistula path and to check for the blockages in the fistula.

Fistulas may be managed by a combination of treatments and may be medically and surgically managed. Studies indicate that the combination of medical and surgical treatment results in the highest healing rate. We will briefly mention here the medicines you can use to alleviate fistula and the surgical options for permanent treatment of Fistula.

Medications:

Antibiotics:

Antibiotics, such as ciprofloxacin and metronidazole, can contribute to lower discharge and comfort your fistula. However, antibiotics seldom lead to a total and durable cure. It normally takes 6 to 8 weeks for fistulas to respond to antibiotics, treatment often lasts for several months.

2. Azathioprine:

Azathioprine (and mercaptopurine less frequently used) have been shown to aid the closure of fistulas, though it is not efficient in everyone. You can keep your fistula closed for some time (a few years) if this works. As azathioprine is slow to operate, antibiotics are often employed as initial treatment before azathioprine takes effect (it may take 3 to 6 months before people notice benefits). Studies show that azathioprine is more effective in combination with antibiotics.

3. Biologic or anti-TNF drugs:

You may be prescribed one of the biological (or Anti-TNF) drugs, if antibiotics and azathioprine do not appear helpful. Infliximab, adalimumab and certolizumab have been shown to help heal the fistulas. These treatments are probably last for at least one year. NICE (National Institute of Health and Care Excellence) recommends biologic treatment for patients with severe fistulas of Crohn's disease.

Additional medicines: Ciclosporin tacrolimus, methotrexate and thalidomide are also sometimes used to treat anal fistulas.

Anal Fistula Treatment in Delhi

Two surgical approaches for Anal Fistula are available: Traditional and modern techniques.

A) Traditional Technique include:

1. Fistulectomy: This process involves opening the entire length of the fistula to allow the surgeon to remove the whole content of the fistula. The tract of the fistula is removed and the small hole formed is left to heal. This procedure presents the risk that the sphincter muscle will be damaged and this results in faecal incontinence and is usually used to treat complex anal fistula.

B) Modern Technique include:

Video Assisted Anal Fistula Treatment (VAAFT): The technique allows the fistula path directly to be viewed from the inside with a telescope. The fistula can be cauterized(sealed) after cleaning by electric current to close the track. You can also use stitches and fibrin glue. This is a new method that can help surgeons to find additional passages that run off the main fistula and that require treatment to cure the fistula.

Mucosal advancement flap procedure:The inner lining of the rectum will be lifted and pushed down into the anal canal to close the inner hole following cleaning of the fistula (leaving the muscles intact). The procedure is used for complex fistulas involving the sphincter muscles, which carry a high risk of incontinence when cutting the fistula track open.

Setons: Loose Setons are soft operational threads that go through the fistula channel and the anus via which a loop with its protruding ends is connected to. The Seton is a "wick" that removes infected tissue or pus. If the fistula heals or stays in place for long periods, it may be removed. Studies show that adding loose setons in treatment with infliximab improves results for people with anal fistulas. People report that a loose seton is like a rubber band hanging from the anus, and they don't notice it's there any more after a few days.

A cutting seton: is an alternative, where the thread is slowly tightened over a period of months to slowly move the seton through the muscle and fistula, forming the scar tissue and closing the fistula. Though cure with a cutting seton can be used for 4 out of 5 people, the rate of incontinence can be high, so the procedure is seldom used now.

4. Ligation of Intersphincteric Fistula tract (LIFT):is a technique used for the treatment of a deep or complex anal fistula. A seton is placed in the tract for some time, which forces it to widen. The surgeon removes the infected tissue a few weeks later and closes the opening of the internal fistula.

5. Fistula plug: A plug for fistula is a plug that is a 100% bio-absorbable scaffold. The fistula plug is put in the tract of fistula. During a certain time, the cells from the body move into the scaffold and the body absorbs the plug material that does not leave permanent material in the body.

6. Fistula-tract laser closure (Filac): It's made with laser Leonardo. This procedure helps the fistula tract to be removed carefully without damaging the sphincter muscle.

7. Distal Ligation Proximal laser (DLPL): This procedure is not only intended to treat fistula but also to save the sphincter muscle which helps prevent incontinence and recurrence. In this fistula treatment, the abscess cavity with the internal opening is first removed and the distal tract is then closed. The nearby area of the fistula tract is then sealed using the Leonardo laser that helps complete track closing.

Why to choose Glamyo Health for Anal Fistula Treatment in Delhi?

You can get your surgery done by Glamyo Health’s experienced surgeons in the best hospital of Delhi. You just need to visit the website and call our medical counsellors for more information about your Anal Fistula treatment in Delhi.